Inappropriate secretion of human placental lactogen and β-subunit of human chorionic gonadotropin by cancer of the uterine cervix

Sheth, Nandini A.; Adil, M A; Nadkarni, Jayashree J.; Rajpal, R. M.; Sheth, A. R.

doi:10.1016/0090-8258(81)90046-9

Gynecologic Oncology

1981

DOI: 10.1016/0090-8258(81)90046-9

|View full text |Cite

Inappropriate secretion of human placental lactogen and β-subunit of human chorionic gonadotropin by cancer of the uterine cervix

Nandini A. Sheth¹,

M A Adil²,

Jayashree J. Nadkarni³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1987

1989

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Pros and cons of gynecologic tumor markers

Bast¹,

Hunter²,

Knapp³

1987

Cancer

View full text Add to dashboard Cite

The use of a tumor marker not only depends upon its sensitivity and specificity, but also upon its ability to influence decisions between alternative plans for patient management. Use of beta human chorionic gonadotropin (hCG) for monitoring gestational trophoblastic neoplasia has set the standard to which other assays must be compared. Beta hCG and alphafetoprotein have provided useful markers for ovarian germ cell tumors. Recently, a monoclonal antibody-based immunoassay for CA 125 antigen has been used to monitor the treatment of epithelial ovarian carcinomas. Persistent elevation of CA 125 in serum has generally reflected persistence of disease at second look surveillance procedures. CA 125 levels can, however, return to within normal limits and residual disease can be found at laparoscopy or laparotomy. CA 125 shows promise for distinguishing benign from malignant pelvic masses. Trials are currently underway to evaluate the potential of CA 125 in combination with other markers to facilitate earlier detection of occult ovarian cancer.

show abstract

Pros and cons of gynecologic tumor markers

Bast¹,

Hunter²,

Knapp³

1987

Cancer

View full text Add to dashboard Cite

show abstract

Adenocarcinoma of the uterine cervix with β-hCG production: A case report and review of the literature

Collins¹,

Wong²

1989

Gynecologic Oncology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Inappropriate secretion of human placental lactogen and β-subunit of human chorionic gonadotropin by cancer of the uterine cervix

Cited by 2 publications

References 14 publications

Pros and cons of gynecologic tumor markers

Pros and cons of gynecologic tumor markers

Adenocarcinoma of the uterine cervix with β-hCG production: A case report and review of the literature

Contact Info

Product

Resources

About